MDGL Annual Cash & Cash Equivalents
$99.92 M
-$231.63 M-69.86%
31 December 2023
Summary:
As of January 23, 2025, MDGL annual cash & cash equivalents is $99.92 million, with the most recent change of -$231.63 million (-69.86%) on December 31, 2023. During the last 3 years, it has risen by +$45.91 million (+85.01%). MDGL annual cash & cash equivalents is now -69.86% below its all-time high of $331.55 million, reached on December 31, 2022.MDGL Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MDGL Quarterly Cash And Cash Equivalents
$232.68 M
-$261.91 M-52.95%
30 September 2024
Summary:
As of January 23, 2025, MDGL quarterly cash and cash equivalents is $232.68 million, with the most recent change of -$261.91 million (-52.95%) on September 30, 2024. Over the past year, it has dropped by -$261.91 million (-52.95%). MDGL quarterly cash and cash equivalents is now -62.62% below its all-time high of $622.52 million, reached on March 31, 2024.MDGL Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MDGL Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -69.9% | -53.0% |
| 3 y3 years | +85.0% | -53.0% |
| 5 y5 years | +74.1% | -53.0% |
MDGL Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -69.9% | +175.5% | -62.6% | +541.5% |
| 5 y | 5-year | -69.9% | +175.5% | -62.6% | +593.8% |
| alltime | all time | -69.9% | >+9999.0% | -62.6% | >+9999.0% |
Madrigal Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $232.68 M(-53.0%) |
| June 2024 | - | $494.60 M(-20.5%) |
| Mar 2024 | - | $622.52 M(+523.0%) |
| Dec 2023 | $99.92 M(-69.9%) | $99.92 M(+61.0%) |
| Sept 2023 | - | $62.05 M(-19.6%) |
| June 2023 | - | $77.20 M(-31.9%) |
| Mar 2023 | - | $113.31 M(-65.8%) |
| Dec 2022 | $331.55 M(+814.1%) | $331.55 M(+458.7%) |
| Sept 2022 | - | $59.34 M(+11.4%) |
| June 2022 | - | $53.27 M(+26.0%) |
| Mar 2022 | - | $42.28 M(+16.6%) |
| Dec 2021 | $36.27 M(-32.8%) | $36.27 M(-26.2%) |
| Sept 2021 | - | $49.17 M(+46.6%) |
| June 2021 | - | $33.54 M(-24.1%) |
| Mar 2021 | - | $44.20 M(-18.1%) |
| Dec 2020 | $54.00 M(+15.6%) | $54.00 M(-50.5%) |
| Sept 2020 | - | $109.12 M(+76.4%) |
| June 2020 | - | $61.87 M(-7.2%) |
| Mar 2020 | - | $66.65 M(+42.7%) |
| Dec 2019 | $46.70 M(-18.6%) | $46.70 M(-47.8%) |
| Sept 2019 | - | $89.49 M(+23.4%) |
| June 2019 | - | $72.51 M(+52.7%) |
| Mar 2019 | - | $47.49 M(-17.2%) |
| Dec 2018 | $57.38 M(-61.4%) | $57.38 M(+50.8%) |
| Sept 2018 | - | $38.05 M(-85.6%) |
| June 2018 | - | $264.86 M(+594.7%) |
| Mar 2018 | - | $38.13 M(-74.3%) |
| Dec 2017 | $148.63 M(+676.3%) | $148.63 M(+1046.8%) |
| Sept 2017 | - | $12.96 M(-62.8%) |
| June 2017 | - | $34.80 M(+323.6%) |
| Mar 2017 | - | $8.21 M(-57.1%) |
| Dec 2016 | $19.14 M(+6152.4%) | $19.14 M(+128.1%) |
| Sept 2016 | - | $8.39 M(-22.0%) |
| June 2016 | - | $10.76 M(-74.9%) |
| Mar 2016 | - | $42.81 M(>+9900.0%) |
| Dec 2015 | $306.20 K | $306.20 K(-99.3%) |
| Sept 2015 | - | $45.54 M(+42.3%) |
| June 2015 | - | $32.00 M(-3.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $33.26 M(-27.7%) |
| Dec 2014 | $46.02 M(-5.1%) | $46.02 M(-32.8%) |
| Sept 2014 | - | $68.48 M(-29.3%) |
| June 2014 | - | $96.81 M(+86.1%) |
| Mar 2014 | - | $52.03 M(+7.3%) |
| Dec 2013 | $48.49 M(-40.5%) | $48.49 M(+90.3%) |
| Sept 2013 | - | $25.48 M(-24.6%) |
| June 2013 | - | $33.78 M(-3.4%) |
| Mar 2013 | - | $34.96 M(-57.1%) |
| Dec 2012 | $81.51 M(+171.0%) | $81.51 M(+176.9%) |
| Sept 2012 | - | $29.44 M(+15.0%) |
| June 2012 | - | $25.59 M(-25.9%) |
| Mar 2012 | - | $34.55 M(+14.9%) |
| Dec 2011 | $30.07 M(-3.9%) | $30.07 M(+45.7%) |
| Sept 2011 | - | $20.64 M(-20.3%) |
| June 2011 | - | $25.89 M(+49.0%) |
| Mar 2011 | - | $17.37 M(-44.5%) |
| Dec 2010 | $31.31 M(-29.1%) | $31.31 M(-10.3%) |
| Sept 2010 | - | $34.91 M(-18.1%) |
| June 2010 | - | $42.61 M(-26.4%) |
| Mar 2010 | - | $57.92 M(+31.2%) |
| Dec 2009 | $44.16 M(-15.2%) | $44.16 M(+26.9%) |
| Sept 2009 | - | $34.80 M(+9.2%) |
| June 2009 | - | $31.88 M(-22.5%) |
| Mar 2009 | - | $41.16 M(-20.9%) |
| Dec 2008 | $52.05 M(-55.0%) | $52.05 M(-10.9%) |
| Sept 2008 | - | $58.40 M(-26.4%) |
| June 2008 | - | $79.38 M(-20.0%) |
| Mar 2008 | - | $99.21 M(-14.2%) |
| Dec 2007 | $115.58 M(+243.1%) | $115.58 M(+139.1%) |
| Sept 2007 | - | $48.34 M(-25.1%) |
| June 2007 | - | $64.53 M(-16.1%) |
| Mar 2007 | - | $76.88 M(+128.2%) |
| Dec 2006 | $33.69 M(+41.5%) | $33.69 M(-19.4%) |
| Sept 2006 | - | $41.80 M(+75.6%) |
| Dec 2005 | $23.81 M(-44.3%) | $23.81 M(-10.1%) |
| Mar 2005 | - | $26.49 M |
| Dec 2004 | $42.74 M(+18.5%) | - |
| Dec 2003 | $36.06 M | - |
FAQ
- What is Madrigal Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Madrigal Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Madrigal Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of MDGL is $99.92 M
What is the all time high annual cash & cash equivalents for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual cash & cash equivalents is $331.55 M
What is Madrigal Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, MDGL annual cash & cash equivalents has changed by -$231.63 M (-69.86%)
What is Madrigal Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of MDGL is $232.68 M
What is the all time high quarterly cash and cash equivalents for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly cash and cash equivalents is $622.52 M
What is Madrigal Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, MDGL quarterly cash and cash equivalents has changed by -$261.91 M (-52.95%)